SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT
Compounds of Formula (I) or (Ia) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or (Ia) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
1 . A compound of the Formula (I)
wherein:
R 1 is selected from the group consisting of H and C 1 -C 6 alkyl;
R 2 and R 3 are independently selected from the group consisting of:
(i) H;
(ii) C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is unsubstituted or substituted by 1 to 2 R a substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, C 1 -C 3 alkylsulfonyl, C 2 -C 4 acyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 hydroxycarbonyl, oxo (═O), C 3 -C 8 cycloalkyl, and 4- to 10-membered mono- or bicyclic heterocycloalkyl;
wherein the C 3 -C 8 cycloalkyl or the 4- to 10-membered mono- or bicyclic heterocycloalkyl of R a is unsubstituted or substituted by 1 to 2 substituents selected from the group consisting of halo, hydroxy, amino, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, and C 1 -C 3 alkoxy; and
(iii) a 3- to 8-membered monocyclic, bridged bicyclic, or spirocyclic saturated ring system containing 0 to 2 heteroatom groups selected from the group consisting of N, O, S, S(O), S(O) 2 , P, P(O), and P(O) 2 ;
wherein the 3- to 8-membered monocyclic, bridged bicyclic, or spirocyclic saturated ring system is unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, C 1 -C 3 alkylsulfonyl, C 2 -C 4 acyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxy(C 1 -C 3 )alkyl, carboxy, and C 1 -C 3 alkoxycarbonyl;
or alternatively, R 2 and R 3 together with the N atom to which they are attached form a 4- to 9-membered monocyclic, fused bicyclic, bridged bicyclic, or spirocyclic saturated ring system containing 0 to 2 additional heteroatoms selected from the group consisting of N, O, and S;
wherein the 4- to 9-membered monocyclic, fused bicyclic, bridged bicyclic, or spirocyclic saturated ring system is unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, C 1 -C 4 hydroxyalkyl, C 3 -C 5 hydroxycycloalkyl, —(CH 3 ) 2 N(C═O)CH 2 —, CH 3 (C═O)NHCH 2 —, and C 1 -C 3 alkoxy(C 1 -C 3 )alkyl;
or alternatively, one of R 2 and R 3 together with the N atom to which it is attached and an adjacent C atom form a 3- to 6-membered monocyclic saturated ring system containing 0 to 2 additional heteroatoms selected from the group consisting of N, O, and S;
wherein the 3- to 6-membered monocyclic saturated ring system is unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, C 1 -C 3 hydroxyalkyl, and C 1 -C 3 alkoxy(C 1 -C 3 )alkyl;
at each occurrence R 4 is independently selected from the group consisting of halo, cyano, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, and C 1 -C 4 cyanoalkyl;
E 1 , E 2 , E 3 , and E 4 are independently selected from the group consisting of N and C, with the proviso that no more than three of E 1 , E 2 , E 3 , and E 4 are N;
one of B 1 and B 3 is C and the other is N;
B 2 is N or C(R B ), wherein R B is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 3 -C 6 cycloalkyl;
at each occurrence R L is independently selected from the group consisting of fluoro, hydroxy, C 1 -C 6 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl, oxo (═O), C 2 -C 4 acyl, and methenyl (═CH 2 ), or alternatively, two geminally substituted R L substituents together with the carbon atom to which they are attached form a 3- to 6-membered spirocyclic ring containing 0 to 1 heteroatoms selecting from the group consisting of N, O, and S;
ring A a is present or absent, and if present, is a 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S;
X 1 , X 2 , X 3 , X 4 , and X 5 are independently selected from the group consisting of N and C, with the proviso that no more than two of X 1 , X 2 , X 3 , X 4 , and X 5 are N;
at each occurrence R 5 is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 3 alkoxy, C 1 -C 3 acyl, halo, hydroxy, amino, cyano, oxo (═O), C 1 -C 4 cyanoalkyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, C 1 -C 3 alkoxy(C 1 -C 3 )alkyl, and a group of the formula
at each occurrence R 6 is independently selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, halo, hydroxy, oxo (═O), cyano, carbamoyl, C 1 -C 4 cyanoalkyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxy(C 1 -C 3 )alkyl, C 3 -C 6 cycloalkyl, and C 1 -C 4 carbamoylalkyl;
each occurrence of R 7 is independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, and C 1 -C 3 alkoxy;
A 1 is selected from the group consisting of —CH 2 —, —CH 2 —N(R L )—, —C(═O)—N(R L )—, —CH 2 —O—, —C(H)(R L )—, —N(H)—, —N(R L )—, —S—, —S(═O)—, and —O—;
Z is selected from the group consisting of H and halo;
subscript m is 0, 1, 2, or 3;
subscript n is 0, 1, 2, or 3;
subscript p is 0, 1, 2, 3, or 4;
subscript q is 0, 1, 2, or 3;
subscript r is 0, 1, 2, or 3; and
subscript s is 0, 1, 2, or 3,
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein:
the C 1 -C 6 alkyl is unsubstituted or substituted by 1 to 2 R a substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, C 1 -C 3 alkylsulfonyl, C 2 -C 4 acyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 hydroxycarbonyl, C 3 -C 8 cycloalkyl, and 4- to 10-membered mono- or bicyclic heterocycloalkyl;
R 2 and R 3 together with the N atom to which they are attached form the 4- to 8-membered saturated heterocycloalkyl having 0 to 2 additional heteroatoms selected from the group consisting of N, O, and S;
wherein the 4- to 8-membered heterocycloalkyl is unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, C 1 -C 3 hydroxyalkyl, and C 1 -C 3 alkoxy(C 1 -C 3 )alkyl;
at each occurrence R L is independently selected from the group consisting of fluoro, hydroxy, C 1 -C 6 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl, oxo (═O), and methenyl (═CH 2 ),
the ring A a is present or absent, and if present, is the 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S;
at each occurrence R 5 is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 3 alkoxy, C 1 -C 3 acyl, halo, hydroxy, amino, cyano, oxo (═O), C 1 -C 4 cyanoalkyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, C 1 -C 3 alkoxy(C 1 -C 3 )alkyl, and the group of the formula
at each occurrence R 6 is independently selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkoxy, halo, hydroxy, oxo (═O), cyano, carbamoyl, C 1 -C 4 cyanoalkyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxy(C 1 -C 3 )alkyl, and C 1 -C 4 carbamoylalkyl;
A 1 is selected from the group consisting of —CH 2 —, —C(H)(R L )—, —N(H)—, —N(R L )—, and —O—;
Z is H; and
subscript q is 0, 1, or 2.
3 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the group
4 . The compound of claim 3 or the pharmaceutically acceptable salt thereof, wherein the group
5 . The compound of claim 4 or the pharmaceutically acceptable salt thereof, wherein R B is H or methyl, and the subscript s is 0.
6 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein:
X 1 is N or C; and
X 2 , X 3 , X 4 , and X 5 are C.
7 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the group
8 . The compound of claim 7 or the pharmaceutically acceptable salt thereof, wherein the group
9 . The compound of claim 7 or the pharmaceutically acceptable salt thereof, wherein the group
R 5 is C 1 -C 3 alkyl or C 1 -C 3 fluoroalkyl; and
R 6 is C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, or C 1 -C 3 alkoxy(C 1 -C 3 )alkyl.
10 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the group
11 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the group
12 . The compound of claim 10 or the pharmaceutically acceptable salt thereof, wherein the group
13 . The compound of claim 12 or the pharmaceutically acceptable salt thereof, wherein the group
14 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the group
15 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are independently H, C 1 -C 6 alkyl, or C 1 -C 6 fluoroalkyl.
16 . The compound of claim 14 or the pharmaceutically acceptable salt thereof, wherein the group
17 . The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein:
(i) the group is
and R B is H and the subscript s is 0;
(ii) the group is
wherein R 5 and R 6 are independently C 1 -C 3 alkyl or C 1 -C 3 fluoroalkyl;
(iii) the group is
(iv) the group
and
(v) the group
18 . The compound or the pharmaceutically acceptable salt thereof of claim 1 selected from Examples 1-300.
19 . A pharmaceutical composition comprising the compound of claim 1 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
20 . A pharmaceutical composition comprising the compound of claim 1 , or the pharmaceutically acceptable salt thereof, an additional anti-cancer agent, and a pharmaceutically acceptable carrier.
21 . A method of inhibiting KRAS G12C protein comprising contacting KRAS G12C protein with the compound of claim 1 , or the pharmaceutically acceptable salt thereof, to inhibit the activity of the KRAS G12C protein.
22 . A method of treating cancer comprising administering a therapeutically effective amount of the compound of claim 1 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
23 . The method of claim 22 , further comprising administering an additional active agent to the subject.
24 .- 30 . (canceled)